ImmuPharma Soars On Avion Lupus Deal
Validates Management Faith In Lupuzor
US speciality drugs group will fund the $25m costs of the UK company's new Phase III trial of Lupuzor, which has been much maligned by analysts.
You may also be interested in...
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.
The coronavirus pandemic hurt the German group's healthcare division but helped the contract development and manufacturing activities of Merck's life sciences business.
Oncology is an area where the Swiss major has long been a dominant player, and Bill Anderson highlighted programs to Scrip which Roche hopes will help extend that dominance.